Quantcast

Industry news that matters to you.  Learn more

Collaboration at Eskenazi Health Explores Ways to Personalize Medicine

In cooperation with Eskenazi Health, the Indiana Institute for Personalized Medicine, the Indiana University School of Medicine and the Regenstrief Institute are evaluating how genetics impact the responsiveness and efficacy of certain drugs. It is believed to be the first study of its kind to examine both the economic and clinical value of implementing personalized medicine.

Personal Genome Diagnostics Study Highlights Limitations of Tumor-only Sequencing for Cancer

Personal Genome Diagnostics, Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, recently announced the publication of a landmark study showing that many of the genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the individual. The study is in the April 15 edition of Science Translational Medicine and was conducted by PGDx scientists working in collaboration with company co-founders Dr. Victor Velculescu and Dr. Luis Diaz, Jr. and their colleagues at Johns Hopkins University.

Oncodesign has Entered into a Services Agreement with Eisai to Develop a New Personalized Medicine Program in Earlier Line Metastatic Breast Cancer Treatment

ONCODESIGN (FR0011766229 – ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, recently announced the signing of an agreement with Eisai Inc. Oncodesign will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign’s patient-derived xenograft models (PDX) to investigate the potential of eribulin mesylate (“eribulin”) in earlier line treatment of metastatic breast cancer.

Strand Life Sciences to Demonstrate New StrandOmics Features at AMP 2014 Annual Meeting

Strand Life Sciences (Strand) representatives will demonstrate new capabilities of the company’s variant interpretation and reporting software, StrandOmics at the Association For Molecular Pathologist (AMP) 2014 Annual Meeting to be held from November 12th to 15th in National Harbor, Maryland. The 20th anniversary meeting’s theme is “Realizing the Dream of Precision Medicine,” with a special address by Dr. Francis Collins, Director of the National Institute of Health. At AMP, Strand will host a workshop on the innovative developments and application of its StrandOmics software, plus new expansion efforts in Personalized Medicine.

IBM and Cleveland Clinic Use Watson to Advance Genomic Research for Cancer Care Pilot

IBM (NYSE: IBM) recently announced a new initiative to accelerate the adoption of genomic based medicine at Cleveland Clinic. Researchers at Cleveland Clinic will use IBM Watson technology in the area of genomic research to help oncologists deliver personalized medicine by uncovering new cancer treatment options for patients.